Your search for rivaroxaban returned 150 results

Your search for rivaroxaban returned 150 results

Sort Results:

Relevant Recent
American College of Cardiology 2011

Rivaroxaban Compares Favorably With Enoxaparin for VTE Prevention in Acute Conditions But Demonstrates No Net Clinical Benefit

Rivaroxaban is non-inferior to enoxaparin in short-term use and superior in long-term use for the prevention of venous thromboembolism (VTE) in acutely ill medical patients, but demonstrates weaker safety outcomes, according to results of the MAGELLAN trial presented today at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
American College of Cardiology 2013

Similar Bleeding and Thrombotic Complication Rates Between Dabigatran and Rivaroxaban

At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, Anil Rajendra, MD, from the Medical University of South Carolina, in Charleston, SC, presented data showing similar bleeding and thrombotic complication rates at the time of atrial fibrillation ablation (AFA) in patients anticoagulated with dabigatran and rivaroxaban. Dr. Rajendra and colleagues determined that rivaroxaban has an acceptable safety profile for AFA.

GI Bleeding Up for New Users of Rivaroxaban

Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation